

UNITED STATES BANKRUPTCY COURT

Western DISTRICT OF Pennsylvania

In Re. Lipella Pharmaceuticals, Inc.

§
§
§
§

Case No. 26-20879

Debtor(s)

☐ Jointly Administered

Monthly Operating Report

Chapter 11

Reporting Period Ended: 08/31/2026

Petition Date: 03/30/2026

Months Pending: 5

Industry Classification:

3	2	5	4
---	---	---	---

Reporting Method:

Accrual Basis ☒

Cash Basis ☐

Debtor's Full-Time Employees (current):

2

Debtor's Full-Time Employees (as of date of order for relief):

6

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- ☒ Statement of cash receipts and disbursements
- ☒ Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
- ☐ Statement of operations (profit or loss statement)
- ☐ Accounts receivable aging
- ☐ Postpetition liabilities aging
- ☐ Statement of capital assets
- ☐ Schedule of payments to professionals
- ☐ Schedule of payments to insiders
- ☒ All bank statements and bank reconciliations for the reporting period
- ☐ Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Jonathan Kaufman

Signature of Responsible Party

09/21/2026

Date

Jonathan Kaufman, CEO

Printed Name of Responsible Party

1159 S Negley Ave
Pittsburgh, PA 15217

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name Lipella Pharmaceuticals, Inc.

Case No. 26-20879

Part 1: Cash Receipts and Disbursements		Current Month	Cumulative
a.	Cash balance beginning of month	\$660,933	
b.	Total receipts (net of transfers between accounts)	\$0	\$207,078
c.	Total disbursements (net of transfers between accounts)	\$11,848	\$242,185
d.	Cash balance end of month (a+b-c)	\$649,085	
e.	Disbursements made by third party for the benefit of the estate	\$0	\$0
f.	Total disbursements for quarterly fee calculation (c+e)	\$11,848	\$242,185

Part 2: Asset and Liability Status (Not generally applicable to Individual Debtors. See Instructions.)		Current Month
a.	Accounts receivable (total net of allowance)	\$0
b.	Accounts receivable over 90 days outstanding (net of allowance)	\$0
c.	Inventory (Book ☐ Market ☐ Other ☒ (attach explanation))	\$0
d.	Total current assets	\$834,224
e.	Total assets	\$834,224
f.	Postpetition payables (excluding taxes)	\$310,315
g.	Postpetition payables past due (excluding taxes)	\$0
h.	Postpetition taxes payable	\$0
i.	Postpetition taxes past due	\$0
j.	Total postpetition debt (f+h)	\$310,315
k.	Prepetition secured debt	\$0
l.	Prepetition priority debt	\$34,300
m.	Prepetition unsecured debt	\$468,309
n.	Total liabilities (debt) (j+k+l+m)	\$812,924
o.	Ending equity/net worth (e-n)	\$21,300

Part 3: Assets Sold or Transferred		Current Month	Cumulative
a.	Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$205,000
b.	Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	\$0	\$0
c.	Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$205,000

Part 4: Income Statement (Statement of Operations) (Not generally applicable to Individual Debtors. See Instructions.)		Current Month	Cumulative
a.	Gross income/sales (net of returns and allowances)	\$0	
b.	Cost of goods sold (inclusive of depreciation, if applicable)	\$0	
c.	Gross profit (a-b)	\$0	
d.	Selling expenses	\$0	
e.	General and administrative expenses	\$-23,061	
f.	Other expenses	\$2,475	
g.	Depreciation and/or amortization (not included in 4b)	\$0	
h.	Interest	\$0	
i.	Taxes (local, state, and federal)	\$0	
j.	Reorganization items	\$-4,811	
k.	Profit (loss)	\$15,774	\$-374,138

Debtor's Name Lipella Pharmaceuticals, Inc.

Case No. 26-20879

Part 5: Professional Fees and Expenses

a.			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
	Debtor's professional fees & expenses (bankruptcy) <i>Aggregate Total</i>		\$89,945	\$89,945	\$59,945	\$59,945
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i	BDO Consulting Group, LLC	Financial Professional	\$89,945	\$89,945	\$59,945	\$59,945
ii						
iii						
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						

Debtor's Name Lipella Pharmaceuticals, Inc.

Case No. 26-20879

xxxvii						
xxxvii						
xxxix						
xl						
xli						
xlII						
xlIII						
xliv						
xlV						
xlvi						
xlVII						
xlVIII						
xlIX						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						

Debtor's Name Lipella Pharmaceuticals, Inc.

Case No. 26-20879

lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc i						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						

b.			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
	Debtor's professional fees & expenses (nonbankruptcy) <i>Aggregate Total</i>		\$179,144	\$179,144	\$0	\$0
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i	Tucker Arensberg, P.C.	Lead Counsel	\$179,144	\$179,144	\$0	\$0
ii						
iii						
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						

Debtor's Name Lipella Pharmaceuticals, Inc.

Case No. 26-20879

xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						

Case No. 26-20879

lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc i						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						

Debtor's Name Lipella Pharmaceuticals, Inc.

Case No. 26-20879

c.	xcix						
	c						
All professional fees and expenses (debtor & committees)							\$0

Part 6: Postpetition Taxes

Current Month

Cumulative

a.	Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b.	Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c.	Postpetition employer payroll taxes accrued	\$0	\$0
d.	Postpetition employer payroll taxes paid	\$0	\$12,996
e.	Postpetition property taxes paid	\$0	\$0
f.	Postpetition other taxes accrued (local, state, and federal)	\$0	\$0
g.	Postpetition other taxes paid (local, state, and federal)	\$0	\$922

Part 7: Questionnaire - During this reporting period:

- a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes ☐ No ☒
- b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions) Yes ☐ No ☒
- c. Were any payments made to or on behalf of insiders? Yes ☐ No ☒
- d. Are you current on postpetition tax return filings? Yes ☒ No ☐
- e. Are you current on postpetition estimated tax payments? Yes ☒ No ☐
- f. Were all trust fund taxes remitted on a current basis? Yes ☒ No ☐
- g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions) Yes ☐ No ☒
- h. Were all payments made to or on behalf of professionals approved by the court? Yes ☒ No ☐ N/A ☐
- i. Do you have:
- Worker's compensation insurance? Yes ☐ No ☒
 - If yes, are your premiums current? Yes ☐ No ☐ N/A ☒ (if no, see Instructions)
 - Casualty/property insurance? Yes ☐ No ☒
 - If yes, are your premiums current? Yes ☐ No ☐ N/A ☒ (if no, see Instructions)
 - General liability insurance? Yes ☐ No ☒
 - If yes, are your premiums current? Yes ☐ No ☐ N/A ☒ (if no, see Instructions)
- j. Has a plan of reorganization been filed with the court? Yes ☐ No ☒
- k. Has a disclosure statement been filed with the court? Yes ☐ No ☒
- l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Debtor's Name Lipella Pharmaceuticals, Inc.

Case No. 26-20879

Part 8: Individual Chapter 11 Debtors (Only)

- | | | |
|--|-------|-----|
| a. Gross income (receipts) from salary and wages | _____ | \$0 |
| b. Gross income (receipts) from self-employment | _____ | \$0 |
| c. Gross income from all other sources | _____ | \$0 |
| d. Total income in the reporting period (a+b+c) | _____ | \$0 |
| e. Payroll deductions | _____ | \$0 |
| f. Self-employment related expenses | _____ | \$0 |
| g. Living expenses | _____ | \$0 |
| h. All other expenses | _____ | \$0 |
| i. Total expenses in the reporting period (e+f+g+h) | _____ | \$0 |
| j. Difference between total income and total expenses (d-i) | _____ | \$0 |
| k. List the total amount of all postpetition debts that are past due | _____ | \$0 |
- l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)? Yes ☐ No ☒
- m. If yes, have you made all Domestic Support Obligation payments? Yes ☐ No ☐ N/A ☒

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/ eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Jonathan Kaufman

Signature of Responsible Party

Chief Executive Officer


Title

Jonathan Kaufman, CEO


Printed Name of Responsible Party

09/21/2026


Date




PageOnePartOne



PageOnePartTwo




PageTwoPartOne




PageTwoPartTwo

Debtor's Name Lipella Pharmaceuticals, Inc.


Case No. 26-20879




Bankruptcy1to50



Bankruptcy51to100




NonBankruptcy1to50




NonBankruptcy51to100

Debtor's Name Lipella Pharmaceuticals, Inc.

Case No. 26-20879



PageThree



PageFour

Summary of Cash Receipts and Disbursements

For the period 8/1/2026 to 8/31/2026 ("Current Period")

	Current Period	Cumulative
Cash Beginning of Period (Book)	\$ 660,933	\$ 684,191
Receipts		
Interest income	\$ -	\$ 2,078
Other	-	205,000
Total Receipts	\$ -	\$ 207,078
Disbursements		
Rent & Storage	\$ 250	\$ 2,465
Payroll - wages & employer taxes	\$ -	\$ 77,979
Payroll - 401K	\$ -	\$ 12,403
Health insurance	\$ -	\$ 18,213
Property & casualty insurance	\$ -	\$ 11,017
Definiti & 401K administration costs	\$ 997	\$ 4,794
ECTD Submit (FDA matters)	\$ 200	\$ 1,450
Accounting software & Tickerpilot	\$ -	\$ 3,679
Utilities	\$ -	\$ 509
NATCO	\$ -	\$ 500
Moving costs	\$ -	\$ 1,639
Local Taxes	\$ -	\$ 922
BDO Consulting Group LLC (1)	\$ 10,000	\$ 90,000
Tucker Arensburg LLP	\$ -	\$ -
Intellectual Property - Legal Fees	\$ -	\$ 650
D&O Insurance	\$ -	\$ -
Dataroom Fees	\$ -	\$ 3,000
Other Administrative	\$ 386	\$ 12,577
Bank Fees	\$ 15	\$ 387
UST Fees	\$ -	\$ -
Total Disbursements	\$ 11,848	\$ 242,185
Net Cash Flow	\$ (11,848)	\$ (35,107)
Cash End of Period (Book)	\$ 649,085	\$ 649,085
Reconciling items	\$ -	\$ -
Cash End of Period (Bank)	\$ 649,085	\$ 649,085

(1) Represents Retainer payments held in Escrow.

Balance Sheet

As at August 31, 2026

	<u>August 31, 2026</u>
Cash	\$ 649,085
Interest Receivable	-
Prepaid Expenses	52,486
Prepaid Retainers	132,654
Lease Accounting	-
PP&E	-
Total Assets	<u>\$ 834,224</u>
AP Pre-Filing	\$ 386,109
AP Post-Filing	3,182
Accrued Liabilities - Post Filing	239,500
Accrued Payroll	184,133
Total Liabilities	<u>\$ 812,924</u>
Retained Earnings	(20,694,488)
Paid Capital	20,715,787
Total Equity	<u>\$ 21,300</u>
Total Liabilities and Equity	<u>\$ 834,224</u>

Income Statement

For the period 8/1/2026 to 8/31/2026 ("Current Period")

	<u>Current Period</u>	<u>Cumulative</u>
Revenue	\$ -	\$ -
Cost of Sales	-	-
Gross Profit	<u>\$ -</u>	<u>\$ -</u>
Operating Expenses		
General & administrative	\$ (23,061)	\$ 202,504
R&D	<u>\$ 2,475</u>	<u>41,850</u>
Total Operating Expenses	<u>\$ (20,586)</u>	<u>\$ 244,354</u>
Non-operating income	(4,811)	159,189
Non-operating expenses	-	288,973
Total Income	<u>\$ 15,774</u>	<u>\$ (374,138)</u>
Income tax expense	-	-
Net Income	<u>\$ 15,774</u>	<u>\$ (374,138)</u>

Bank Reconciliation

As at 8/31/2026 ("Current Period")

Bank Account Number	8/31 Book Balance	Reconciling Items			8/31 Bank Balance
		Outstanding Checks	Deposits in Transit	Other Reconciling Items	
2648	\$ 649,085	\$ -	0	\$ -	\$ 649,085